Medical Device News Magazine

ConcertAI’s TeraRecon Showcases New Clinical and AI Solutions Designed to Enhance Treatment Planning for Structural Heart Patients at TCT 2023

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

ConcertAI’s TeraRecon, a leader in advanced visualization and artificial intelligence (AI) for medical imaging, will showcase its latest innovations and cardiology solutions designed to strengthen clinical confidence, build efficiency throughout the care pathway, and improve cardiac care experiences at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting in San Francisco this week.

Innovation in the Intuition™ solution gives physicians the edge to deliver precise and timely diagnostic interpretations by semi-automating complex image post-processing through tailored advanced clinical workflows. Because it is designed to deliver clinical decision support throughout the enterprise, including radiology, cardiology, neurology, oncology, and vascular surgery, Intuition also enables cross-department consolidation and can eliminate redundant solutions.

The latest version of Intuition, 4.7, adds robust cardiovascular AV functionality through a dedicated Left Atrial Appendage (LAA) workflow, updated Transcatheter Mitral Valve Repair (TMVR) workflow, and various enhancements to streamline cardiac coronary imaging and pre-op planning. These tools provide interventionalists with enhanced visualizations, semi-automated measurements, flexible interaction capabilities, and interoperability designed to streamline procedural planning and eliminate the need for multiple AV solutions.

Cardiology Suite, powered with partners Us2.ai and Coreline Soft, aims to fully automate the analysis and interpretation of echocardiograms and chest CT exams to assess, monitor, and provide insights to help support clinicians in treatment decisions for cardiac patients. Through automated measurements and reports, these AI solutions can help reduce image interpretation times and improve workflows while maintaining accuracy and reducing variability between operators and devices.

Cardiology Suite applications on the Eureka Clinical AI platform are FDA and CE-cleared with additional regional clearances. For full availability of each algorithm, please reach out to TeraRecon. Learn more about the Eureka Clinical AI platform capabilities at www.terarecon.com/artificial-intelligence.

“We are excited to be kicking off the controlled release of FEops HEARTguide™ software in combination with our market leading AV software, Intuition, to enable physicians to better plan and, therefore, better treat patients with LAA closure devices,” said Dan McSweeney, President of TeraRecon. “With the addition of FEops’ advanced Digital Twin clinical AI solution, we are poised to provide clinicians with an unparalleled tool streamlining CT-based preoperative planning for structural heart interventions, leading to more informed decision-making.”

FEops HEARTguide is a unique cloud-based procedure planning solution in the structural heart, based on Digital Twin technologies. With the LAA occlusion workflow, FEops HEARTguide enables U.S. physicians to virtually model different implant positions and sizes of FDA approved LAA devices, aiding physicians in the selection of the optimal size and position for a specific patient. Established clinical evidence from the randomized controlled PREDICT-LAA trial has shown that FEops’ Digital Twin-based planning for LAA closure results in improved procedure efficiency and outcomes as compared to standard CT based planning.

Stop by booth #2241 on Tuesday, October 24, 2-4pm, or Wednesday, October 25, 2-4pm, to meet our newest collaborator and see their state-of-the-art FEops HEARTguide solution, the latest AI-powered device simulation to support preoperative planning procedures for LAA occlusion.

TeraRecon will also be hosting two physician-led presentations in booth #2241 during TCT 2023:

Tuesday, October 24, 12:30 PM – Dr. Serge C. Harb, MD, FACC will be presenting Cardiac CT in Planning Structural Interventions: A Case-based and Hands-on Approach.
Wednesday, October 25, 12:30 PM – Dr. Devi Nair, MD, FACC, FHRS will be presenting Novel Device Simulation for CT-based Preoperative Planning in LAA Closure.

Schedule a meeting or demo to learn more about these new technologies at #TCT23:
https://www.terarecon.com/tct-2023-meeting-request-0

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”